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Abstract 
 
Purpose: Vincristine is known to interfere with OATP-mediated uptake of other compounds, 
hinting that vincristine itself could be a substrate of OATP transporters. The present study 
therefore aimed to investigate the role of OATP transporters in the hepatocellular disposition of 
vincristine.  
Methods: Vincristine uptake was studied in suspended rat and human hepatocytes as well as 
OATP-transfected Chinese hamster ovary (CHO) cells in the absence and presence of OATP 
transporter inhibitors. Membrane vesicles containing MDR1 or MRP1/2/3 were used to directly 
assess the role of these efflux transporters in vincristine disposition. 
Results: Uptake in suspended rat hepatocytes was temperature-dependent and could be inhibited 
by a range of OATP inhibitors. Furthermore, the MRP-inhibitor benzbromarone, but none of the 
tested MDR1 inhibitors, reduced vincristine efflux in rat and human suspended hepatocytes. 
OATP1B1-, OATP1B3- and OATP2B1- transfected CHO cells showed significantly increased 
vincristine uptake as compared to wild-type cells. Moreover, uptake in OATP-transfected CHO 
cells was reduced by OATP inhibitors. However, uptake studies in suspended human hepatocytes 
showed that only 10% of the total vincristine uptake process could be attributed to OATP-
mediated transport. Studies with transporter-expressing membrane vesicles confirmed vincristine 
as an MDR1 substrate, while MRP1/2/3-mediated transport of vincristine could not be observed 
with this model system. 
Conclusions: Our findings show the involvement of OATP transporters in the disposition of 
vincristine in rat and human hepatocytes. However, in both species, hepatic uptake is 
overshadowed by a benzbromarone-sensitive efflux mechanism, possibly MRP3.  
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Abbreviations 
ABC  ATP-binding cassette 
CHO  Chinese hamster ovary 
Cl  Clearance 
MRP  Multidrug resistance-associated protein 
OATP  Organic anion transporting polypeptide 
RAF  Relative activity factor 
SHH  Suspended human hepatocytes 
SLC  Solute carrier 
SRH  Suspended rat hepatocytes 
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Introduction 
Since its identification in the early 60’s in extracts originating from the Catharantus roseus flower 
(Madagascar periwinkle), vincristine has been a key chemotherapeutic drug for the treatment of 
both adult and pediatric cancer patients (1). Vincristine is a cornerstone during the induction, 
intensification and consolidation phases in the treatment of acute lymphoblastic leukemia (2, 3). 
Moreover, it is indicated for Hodgkin lymphoma, non-Hodgkin lymphoma, neuroblastoma, 
rhabdomyosarcoma and Wilms tumor (4). Vincristine cytotoxicity arises from microtubule 
binding, which disrupts the mitotic spindle during cell division, causing cell cycle arrest and 
inducing apoptosis (5). This mechanism of action requires an adequate intracellular exposure. 
However, intracellular vincristine concentrations are hard to predict due to drug resistance factors 
such as P-gp/ABCB1/MDR1 and members of the MRP/ABCC family (6). Additionally, large 
inter-individual variability in vincristine pharmacokinetics (>30%) as well as a high risk for dose-
dependent vincristine-induced neuropathy hamper selection of a suitable dose (5). A thorough 
understanding of vincristine disposition could help identify key mechanisms underlying 
vincristine pharmacokinetics, pharmacodynamics and toxicity. Incorporation of this information 
into physiologically-based pharmacokinetic (PBPK) and population-PK models, could aid in 
improving patient-specific dosing guidelines. Vincristine pharmacokinetics is defined by a large 
volume of distribution (160 L/m2) and a relatively long terminal elimination half-life (8.2 h), 
determined primarily by hepatobiliary elimination and to a lesser extent by renal elimination (7). 
Initial studies with radiolabeled vincristine showed a 40-fold higher vincristine concentration in 
the bile as compared to plasma (8). These studies also indicated that after 72 hours, 8 to 15% of 
the administered dose can be found in urine and about 70% can be recovered from feces, of 
which 50 to 60% unchanged. Even though only 50% of the administered dose is metabolized, 
CYP3A5 expression has been inversely correlated with the risk of developing vincristine-induced 
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neuropathy (9). Additionally, concomitant treatment of vincristine with CYP3A4/5 inhibitors, 
like the azole-type antifungals, increases the risk for vincristine-induced neuropathy (10). 
Notably, CYP3A5-mediated vincristine clearance is 9 to 14-fold higher as compared to CYP3A4-
mediated clearance (11). Consequently, CYP3A4 only contributes significantly to vincristine 
metabolism in CYP3A5 non-expressers (11-13). Apart from CYP3A4/5, vincristine is also a 
substrate for several ABC-transporters i.e.: P-gp/ABCB1/MDR1 (14), MRP1/ABCC1 (15) and 
MRP2/ABCC2 (16). Furthermore, presence of MRP3/ABCC3 (17), MRP7/ABCC10 (18), 
ABCB6 (19) and RALBP1 (20) have been shown to increase resistance to vincristine toxicity. 
Resistance to chemotherapeutics due to (enhanced) expression and action of efflux transporters 
received a lot of attention in the past. More recently, the importance of SLC-transporters for the 
uptake of chemotherapeutics into tumor cells and for pharmacokinetics of chemotherapeutics has 
also gained a lot of interest (21-23). Overexpression of SLC-transporters (e.g. OATP1B3) in 
certain cancer types could sensitize tumor cells for chemotherapeutics which are substrates of 
these uptake transporters. Yet, apart from the chemo-sensitizing effect of the kidney-specific 
OCT3/SLC22A3 transporter in kidney carcinoma cell lines (24), no uptake transporter has been 
linked to vincristine disposition. Nevertheless, some reports show that vinca-alkaloids can 
accumulate strongly in HL-60 cells and interact with carrier-mediated processes in rat/human 
hepatocytes and murine leukemia cells (25-28). Additionally, vincristine has been shown to 
interfere with OATP1B1- and OATP1B3-mediated substrate transport (29-31). Therefore, the 
aim of the present work was to investigate whether hepatic isoforms of the OATP transporter 
family play a role in the hepatocellular disposition of vincristine in rat and human hepatocytes. 
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Materials and Methods 
 
Materials  
Vincristine-sulfate was acquired from LC chemicals (Woburn, Massachusetts); vinblastine (1 
mg/ml) as well as methotrexate (2.5 mg/ml) were obtained from TEVA Pharma Belgium 
(Wilrijk, Belgium). Atazanavir-sulfate was obtained through the NIH Aids Reagent Program. 
Benzbromarone, bromosulphophthalein, 5(6)-Carboxy-2′,7′-dichlorofluorescein (CDCF), 
digoxine, glibenclamide, losartan, paclitaxel, paraffin oil, L-proline, rifampycine, rifamycine SV 
and silicon oil (AP150) were purchased from Sigma-Aldrich (Schnelldorf, Germany). Dulbecco’s 
modified eagle medium (DMEM; 1g/L glucose, 25 mM HEPES), fetal bovine serum (heat-
inactivated) (FBS), L-glutamine (200 mM), Hanks’ Balanced Salt Solution (HBSS), penicillin-
streptomycin mixture (10,000 IU potassium penicillin and 10,000 IU streptomycin sulfate per ml 
in 0.85 % saline), phosphate buffered saline (PBS), trypsine- EDTA mixture (170 U/ml and 200 
mg/L, respectively) and Trypan blue stain (0.4 %) were obtained from Westburg (Leusden, The 
Netherlands). Dimethylsulfoxide (DMSO), methanol (MeOH) and Na-pyruvate were purchased 
from Acros Organics (Geel, Belgium). CaCl2 and NaHCO3 were obtained from Chem-lab NV 
(Zedelgem, Belgium) and NaCl from Fisher Chemical (Landsmeer, The Netherlands). 
Geneticine-sulfate was purchased from Life Technologies (Paisley, UK) and HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) from MP Biochemical (Illkrich, France). 
MgCl2.7H2O was obtained from Analar-Normapur (VWR) (Leicestershire, England) and KCl 
from AppliChem GmbH (Darmstadt, Germany). Cyclosporine A was purchased from Sequoia 
Research Products LTD (Pangbourne, UK). MK-571 was obtained from Merck chemicals 
(Overijse, Belgium) and docetaxel from Avantis Pharma (Diegem, Belgium). Quinidine-sulfate 
was purchased from Unibios lab (Mumbai, India) and Formic acid (LC-MS grade) from 
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Biosolve-chemicals (Valkenswaard, The Netherlands). Control, MRP1, MRP2, MRP3 and 
MDR1 inside-out membrane vesicles were purchased from ThermoFisher Scientific (Waltham, 
MA USA). Estradiol 17-(β-D-Glucuronide) was purchased from Sanbio (Uden, The 
Netherlands). 
 
Animals  
Male Wistar rats were purchased from Janvier (Le Genest Saint Isle, France) and housed 
according to Belgian and European laws, guidelines and policies for animal experiments, animal 
housing, and animal care in the Central Animal Facility of the KU Leuven. All experiments 
involving lab animals were approved by The Institutional Ethical Committee for Animal 
Experimentation (license number: LA 1210261). 
 
Vincristine uptake in suspended rat hepatocytes 
Suspended hepatocytes from Wistar rats (190-200g) were isolated according to the two-step 
collagenase perfusion method, cryopreserved and thawed as described previously. (32). Freshly-
isolated hepatocytes were suspended in Krebs-Henseleit buffer (KHB) (118 mM NaCl; 5.17 mM 
KCl; 1.2 mM CaCl2; 1.2 mM MgCl2; 23.8 mM NaHCO3; 12.5 mM HEPES; 11.1 mM Glucose; 5 
mM Na-pyruvate; pH 7.4) sparged with carbogen (95%:5% O2:CO2) and kept at 4°C until the 
start of the experiment. Viability and cell density were evaluated using the Trypan blue (0.04%) 
exclusion method and  counting on a hemocytometer. Viability of freshly-isolated hepatocytes 
ranged between 90 and 92% and viability of cryopreserved hepatocytes was 81%. Cells were 
diluted to a two-fold concentrated cell density (2 million cells/ml) before the start of experiments. 
Incubations were initiated by adding 175 µL of four-fold concentrated inhibitor solution to 350 
µL of the two-fold concentrated cell suspension in a glass test tube and pre-incubating for 10 min 
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at 37°C. Following the pre-incubation, 175 µl of four-fold concentrated (2 µM) vincristine 
solution in KHB was added. Uptake of vincristine in suspended rat hepatocytes was linear as a 
function of time up to 3 min (data not shown). After 3 min, three 200 µL aliquots of the incubate 
were layered on top of 700 µL of oil (82:18 silicon oil AP150:paraffin oil; density 1.051 g/ml) 
which itself had been layered on top of 300 µL of 8% NaCl solution in 1.5 ml centrifuge tubes. 
Tubes were centrifuged immediately for 3 min at 16,162 g. Following centrifugation, centrifuge 
tubes were placed in ethanol cooled with dry ice (-80°C), where they were kept until the end of 
the experiment. After finishing the experiments, the bottom of the tubes were cut (± 80 µL) and 
collected in glass test tubes. Pellets were lysed by shaking them for 30 min after adding 300 µL 
of 70:30 MeOH:H2O containing 2.5 nM of the internal standard (vinblastine). After the pellets 
were completely disrupted, lysates were collected in 1.5 ml centrifuge tubes and stored at -80°C 
until the day of analysis. 
 
Culturing of Chinese hamster ovary cells 
Wild-type, OATP1B1-, OATP1B3-, and OATP2B1-transfected CHO cells were cultured at 
passage numbers 75–77, 67-69, 67-69 and 27-29, respectively. The CHO cells were grown in a 
humidified incubator (37°C, 5% CO2) in T-75 cm2 culture flasks (Greiner Bio-One, Wemmel, 
Belgium) containing 15 ml of culture medium. Culture medium consisted of DMEM (1g/L 
glucose; 25 mM HEPES) supplemented with 10% FBS, 50 µg/ml L-proline, 100 U/ml penicillin, 
100 µg/ml streptomycin, 2 mM L-glutamine and 110 µg/ml sodium pyruvate. Medium of OATP-
transfected cells was supplemented with 500 µg/ml of geneticin. When cells were 90-100% 
confluent, culture medium was removed and cells were washed two times with 1.5 ml of 
trypsine-EDTA mixture, prewarmed at 37°C. This was followed by adding 2 ml of the trypsine-
EDTA mixture to the cells and keeping them in a humidified incubator (37°C, 5% CO2) for 4 
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min. After cells were detached, trypsinization was stopped by adding 8 ml of culture medium. 
Cells were counted on a hemocytometer and subcultered at a ratio depending on the acquired cell 
count. In preparation of uptake experiments, cells were seeded at a density of 20,000 – 25,000 per 
well in Advanced TCTM 24-well plates (Greiner Bio-One, Wemmel, Belgium). Medium was 
replaced every other day and experiments were performed after CHO-cells reached 90-100% 
confluence on day four after seeding. One day before the experiments, CHO-cells were treated 
with 5 mM of sodium butyrate in culture medium to induce gene expression. 
 
Vincristine uptake in transfected Chinese hamster ovary cells 
On the day of experiments, cell morphology and confluence were visually checked. Cells were 
washed twice with 0.5 ml/well of warm (37°C) HBSS (10 mM HEPES, pH 7.4) and pre-
incubated for 10 min with 250 µL of warm (37°C) KHB with or without a two-fold  concentrated 
uptake transporter inhibitor solution (20 µM). Following pre-incubation, 250 µL of warm (37°C) 
two-fold concentrated vincristine solution (20 µM; KHB) was added. Linearity studies were 
performed to ensure linear uptake of vincristine for at least 3 min (data not shown). After 3 min, 
the incubate was aspirated and cells were washed four times with ice-cold (4°C) HBSS (10 mM 
HEPES, pH 7.4). Subsequently, cells were lysed for 30 min with 300 µl of 70:30 MeOH:H2O 
containing 2.5 nM of vinblastine as internal standard. Lysates were transferred to 1.5 ml 
centrifuge tubes and stored at -80°C until the day of analysis. A control plate was included which 
was incubated with a positive control (sodium fluorescein) to verify OATP activity (data not 
shown). Cells in the control plate were lysed with 300 µL of 0.5% Triton-X in PBS. These lysates 
were used to measure the protein content using a BCA Protein Assay kit (Pierce Chemical, 
Rockford, IL, USA), enabling normalization of uptake rates for protein content. Uptake of 
vincristine in wild-type (Wt)-cells was subtracted from uptake of vincristine in transfected CHO-
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cells to calculate the net uptake, which equals the transporter-mediated component of vincristine 
in the OATP-transfected CHO-cells.  
 
Vincristine uptake in suspended human hepatocytes 
Cryopreserved human hepatocytes were acquired in collaboration with BioreclamationIVT® 
(Brussels, Belgium). Human hepatocytes donor information per batch is shown in Table 1. Cells 
were stored in liquid nitrogen (-196°C) until the day of experiments. On the day of the 
experiment, cells were thawed by gently shaking the vial in a water bath (37°C). When frozen 
liquid was no longer present, the content of the vial was transferred completely into a 50 ml 
Falcon® tube containing warm (37°C) InVitroGROTM HT thawing medium 
(BioreclamationIVT®, Brussels, Belgium). The hepatocyte suspension was centrifuged for 5 min 
(50 g) at 21°C, supernatant was aspirated and the pellet gently resuspended in 1 ml of warm 
(37°C) KHB. Viability and cell density were evaluated using the Trypan blue (0.04%) exclusion 
method and counting on a hemocytometer. Viability of human hepatocytes ranged between 80 
and 92%. Prior to the experiment, cells were diluted to a two-fold concentrated cell density (2 
million cells/ml). Pre-incubation and uptake experiments were performed similar to uptake 
experiments performed with SRH. However, contrary to the oil-spin method applied with SRH, 
direct centrifugation was applied for SHH. This was done because benzbromarone decreased the 
passage of SHH through the oil-layer in a concentration dependent manner (data not shown). 
After 1 min incubations, 200 µL aliquots were transferred to 1.5 ml centrifuge tubes which were 
centrifuged for 30 sec at 16,162 g. Next, supernatants were aspirated and pellets were washed 
with ice cold (4°C) PBS, followed by a repetition of the centrifugation step. Following 
centrifugation, the PBS was aspirated and 300 µL of ice cold (4°C) 8% NaCl was added on top of 
the pellets. After a final centrifugation, centrifuge tubes were placed in ethanol cooled with dry 
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ice (-80°C), where they were kept until the end of the incubations. After finishing the 
experiments, the bottom of the tubes were cut (± 80 µL) and collected in glass test tubes. Pellets 
were lysed by shaking them for 30 min after adding 300 µL of 70:30 MeOH:H2O containing 2.5 
nM of the internal standard (vinblastine). After the pellets were completely disrupted, lysates 
were collected in 1.5 ml centrifuge tubes and stored at -80°C until the day of analysis. 
 
Vincristine uptake in inside-out membrane vesicles 
Just before the experiment, vesicles (control, MRP1, MRP2, MRP3, MDR1) were thawed by 
gently shaking in a water bath (37°C) and were kept on ice (4°C) until dilution. Prior to 
experiments, vesicles (5 mg/mL) were diluted in vesicle uptake buffer (50 mM MOPS-TRIS; 70 
mM KCl; 7.5 mM MgCl2; pH 7) and dispensed (29 µL) in 2 mL Eppendorf® tubes. Diluted 
vesicles were pre-incubated for 5 minutes in a shaking water bath (37°C; 70 rpm). Incubations 
were initiated by addition of 21 µL of reaction mixture in vesicle uptake buffer to obtain 
following final concentrations: 4 mM ATP or AMP; 5 mM reduced glutathione; 0.1% v/v DMSO 
or 100 µM benzbromarone; 200 nM of vincristine or 10 µM of 5(6)-Carboxy-2′,7′-
dichlorofluorescein (CDCF) or estradiol 17-β-D-glucuronide (E17BDG). Positive control 
substrates (CDCF, E17BDG) were incubated for 3 minutes and uptake of vincristine was 
assessed for 5 minutes. Uptake was stopped by addition of 200 µL ice-cold (4°C) stop buffer (40 
mM MOPS-TRIS; 70 mM KCl; pH 7) and subsequent vortexing. Samples were stored at 4°C 
until the end of the experiment. 200 µL of the stopped incubate was filtered using a vacuum 
manifold (Merck-Millipore®) and 96-well 1 µm pore-size glass-fiber filter plates (MSFBN6B10; 
Merck-Millipore®) presoaked with 200 µL ice-cold (4°C) stop buffer. Wells containing 
vincristine were washed 5 times with 200 µL of ice-cold stop buffer containing 1% w/v BSA, 
subsequently 5 times with 200 µL of ice-cold stop-buffer containing 0.05% v/v Tween-20 and 
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finally 5 times with 200 µL of ice-cold stop-buffer (14). Wells of all other substrates were 
washed 5 times with 200 µL of ice-cold stop buffer. Control wells were included to assess the 
extent of substrate binding to the filter plate, the blank and the start-solution. Vincristine samples 
were solubilized using 50 µL of 70:30 MeOH:H2O containing 10 nM of the internal standard 
(vinblastine). E17BDG samples were solubilized using 50 µL of 70:30 MeOH:H2O. CDCF 
samples were solubilized using 50 µL of 10% w/v SDS. After addition of the correct solubilizing 
agent, filter plates were placed on top of a 96-well receiver plate and centrifuged for 1 minute at 
850 g (21°C). Following centrifugation, the solubilizing and centrifugation step were repeated 
once more. For compounds analyzed by LC-MSMS, vincristine and E17BDG, 80 µL of filtrate 
was transferred to deep-well 96-well plates and evaporated under a gentle stream of N2 (45°C). 
Samples were dissolved using 50:50 ACN:H2O, centrifuged and injected onto the LC-MSMS 
system. 80 µL of samples containing CDCF were diluted with 100 µL of NaOH (0.1 M) and 
analyzed using fluorescence spectroscopy  (Ex : 485 nm, Em : 535 nm; Spectramax® M2). 
 
Bioanalysis  
On the day of analysis, samples were thawed, vortexed and centrifuged (20,816 g) for 10 min at 
4°C. The obtained supernatants were transferred into micro-inserts for LC-MS/MS analysis and 
injected directly into the LC-MS/MS system. The Thermo Scientific (San Jose, USA) LC-
MS/MS system comprised an Accela® autosampler, an Accela® pump and TSQ Quantum 
Access® triple quadrupole mass spectrometer equipped with an electrospray ionization (ESI) 
source. A kinetex® XB – C18 column (50 mm x 2.1 mm, 2.6 µm), protected by a SecurityGuard 
ULTRA precolumn (Phenomenex, The Netherlands), was used for chromatographic separation. 
The mobile phase consisted of 0.2% v/v formic acid in ELGA® water (A), methanol (B) and 
ELGA® water (C). Gradient elution was performed at a constant flow rate (400 µL/min) as 
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follows: the mobile phase from the start until 1 min of analysis consisted of 37.5% A, 10% B and 
52.5% C, respectively. The percentage of A was kept constant, while B increased linearly up to 
62.5% during 2 min, followed by an immediate decrease (0.1 min) to 10% B and a re-
equilibration of the system for 1.4 min before the next injection. The total run time was 4.5 min 
and the injection volume amounted to 10 µL (partial loop mode) for SRH/CHO samples while it 
amounted to 25 µL (full loop mode) for SHH samples. The column oven and sample tray 
temperatures were set at 30°C and 15°C, respectively. The MS was operated in positive ion mode 
at a spray voltage of 3,500 V. Argon was used as collision gas at a pressure of 1.5 mTorr. The 
MS was operated in 3-channel selected reaction monitoring (SRM) mode with a scan time of 75 
msec. Transitions monitored were 413.2  353.1 m/z and 413.2  383.2 m/z for vincristine 
(MH2+) and 406.2  272.6 m/z and 406.2  376.2 m/z for vinblastine (MH2+) with retention 
times of 3.02 and 3.14 min for vincristine and vinblastine, respectively. Other ionization 
parameter settings were: capillary temperature (275°C), vaporizing temperature (300°C), sheet 
gas pressure (30 arbitrary units), auxiliary gas pressure (25 arbitrary units) and ion sweep gas 
pressure (0 arbitrary units). Collision energies were 23 and 18 arbitrary units for vincristine and 
24 and 17 arbitrary units for vinblastine, respectively. Quality control concentrations were 0.2 
µM, 0.02 µM and 0.002 µM for SRH/CHO samples, and 0.1 µM, 0.01 µM and 0.001 µM for 
SHH samples. Intra- and interday precision of quality control samples were below 10% for the 
high and middle concentrations and < 15% for the low concentration. The calibration curves were 
linear over 12 points ranging from 500 to 0.25 nM and from 250 to 0.13 nM for SRH/CHO and 
SHH samples, respectively. 
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Data-analysis 
ANOVA (α level of 0.05; Dunnett’s post hoc test) was applied to compare control conditions to 
experiments including inhibitors, using Graphpad Prism® version 5.00 for windows (GraphPad 
Software, Inc., California, USA). The Shapiro-Wilk test for normality was applied to test the 
distribution of SHH data for normality. Subsequently, a grouped two-way Student’s t-test was 
applied (α level of 0.05) to the overall averages to compare the populations with and without 
inhibitor. 
 
Uptake data from CHO-cell experiments were used to estimate the OATP-mediated uptake 
clearance of vincristine in SHH as reported by De Bruyn and coworkers (Equation 1) (33). 
𝐶𝐶𝐶𝐶𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂1𝐵𝐵1/3,𝑆𝑆𝑆𝑆𝑆𝑆 = 𝐶𝐶𝐶𝐶𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂1𝐵𝐵1/3,𝐶𝐶𝑆𝑆𝑂𝑂 × 𝑅𝑅𝑅𝑅𝑅𝑅𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂1𝐵𝐵1/3 
(Equation 1) 
ClOATP1B1/3,SHH is the uptake clearance of vincristine by either OATP1B1 or OATP1B3 predicted 
for SHH. ClOATP1B1/3,CHO is the uptake clearance of vincristine in either OATP1B1- or OATP1B3-
transfected CHO cells and RAFOATP1B1/3 is the relative activity factor determined for OATP1B1 
or OATP1B3 transfected CHO cells with estrone-3-sulfate and CGamF, respectively (Table 2). 
RAF-factors determined by De Bruyn and coworkers were determined on the same OATP-
transfected CHO cells as applied in the present study and a pool of human hepatocytes (Table 1) 
(33). Therefore, we deemed it was justifiable to use the same RAF-factors as determined by De 
Bruyn and coworkers to recalculate the uptake data acquired in CHO cells. 
 
Passive uptake clearance of vincristine in SHH cells (Clpassive,SHH) was estimated from vincristine 
uptake clearance in wild-type CHO cells (ClWt,CHO). After dividing the surface area of CHO cells 
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by the surface area of SHH, a factor of 0.51 was obtained (33). This factor was applied according 
to Equation 2 to correct the ClWt,CHO for the difference in surface area across which passive 
permeation can occur. Thus, Clpassive,SHH was calculated: 
𝐶𝐶𝐶𝐶𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝,𝑆𝑆𝑆𝑆𝑆𝑆 = 𝐶𝐶𝐶𝐶𝑊𝑊𝑊𝑊,𝐶𝐶𝑆𝑆𝑂𝑂0.51  
(Equation 2) 
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Results 
  
Vincristine uptake in suspended rat hepatocytes 
Uptake of vincristine in SRH was found to be temperature-dependent: uptake at 4°C [2.2 ± 0.5 
pmol/(min x million cells)] was significantly lower than uptake at 37°C [5.58 ± 0.5 pmol/(min x 
million cells)] (Figure 1). Additionally, uptake of vincristine in SRH could be inhibited with 
known inhibitors of OATP-mediated transport (10 µM) as shown in Figure 1 (atazanavir, 
bromosulfophthalein, cyclosporine A, docetaxel, glibenclamide, losartan, MK571, methotrexate, 
paclitaxel, rifampicin, rifamycin SV). However, no statistically significantly different uptake was 
observed when vincristine was incubated in the presence of digoxin or quinidine. Increasing 
concentrations of known MRP inhibitors MK571 and benzbromarone significantly increased the 
intracellular accumulation of vincristine in SRH (Figures 2A and 2B). However, at low 
concentrations (10 µM) MK571 also inhibited vincristine uptake. 
 
Vincristine uptake in OATP1B1/1B3/2B1-transfected Chinese hamster ovary cells 
The uptake of vincristine was investigated in CHO cells transfected with human OATP1B1, 1B3 
and 2B1 and compared to uptake in wild-type CHO cells. Under these conditions, uptake of 
vincristine was significantly higher in all of the OATP-transfected CHO cells as compared to the 
uptake in wild-type CHO cells (Figures 3A). Interestingly, uptake in OATP1B3-transfected cells 
[77.7 ± 6.4 pmol/(min x mg protein)] was noticeably higher than the uptake in OATP1B1- [39.6 
± 5.7 pmol/(min x mg protein)] and 2B1-transfected cells [39.3 ± 4.6 pmol/(min x mg protein)]. 
Additionally, uptake of vincristine could be significantly inhibited with known inhibitors of 
OATP-mediated transport (10 µM) as shown in Figure 3B-D (atazanavir, docetaxel, digoxin, 
losartan, methotrexate, paclitaxel, rifamycin SV, benzbromarone). Vincristine uptake could not 
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be saturated in any of these cell lines when incubated at concentrations up to 300 µM (data not 
shown). In view of clinical relevance, higher concentrations of vincristine were not evaluated. 
 
Vincristine uptake in suspended human hepatocytes 
Effect of temperature, rifamycin SV and benzbromarone on the uptake of vincristine in 
suspended human hepatocytes was assessed (Figures 4A-C). In all batches of human hepatocytes, 
a significant decrease of vincristine uptake was observed at 4°C when compared to experiments 
performed at 37°C (Figure 4A). However, the effect of 10 µM rifamycin SV on vincristine 
uptake in SHH was only statistically significant in one batch of human hepatocytes (HRU; p = 
0.0057), in which it decreased by 52.5%. In all other batches, vincristine uptake decreased by 
approximately 10% in the presence of 10 µM rifamycin SV, but these changes were not 
statistically significant (Figure 4B). Also, increasing the rifamycin SV concentration to 100 µM 
did not significantly alter vincristine uptake in SHH (data not shown). Still, in the presence of 
100 µM benzbromarone, vincristine uptake increased to 407 ± 105% in all batches of SHH as 
compared to the control condition (p < 0.0001), suggesting an involvement of an MRP-mediated 
efflux process.  
 
Vincristine uptake data from OATP-transfected CHO cells were converted for comparison with 
uptake data obtained in SHH, by using previously reported RAF factors (Table 3) (33). A good 
match was observed between passive uptake clearance estimated from uptake in wild-type CHO 
cells [4.1 ± 0.5 µl/(min x million cells)] and passive uptake clearance observed in SHH at 4°C 
[3.8 ± 1.3 µl/(min x million cells)]. However, a big difference was observed between active 
uptake clearance predicted from CHO cells [1.9 ± 0.3 µl/(min x million cells)] and the measured 
active uptake clearance [10.1 ± 1.5 µl/(min x million cells)]. The predicted OATP-mediated 
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uptake clearance in SHH [1.9 ± 0.3 µl/(min x million cells)] only amounted to 14% of the 
observed total uptake clearance in SHH. However, this corresponds to the small (10%) but 
statistically insignificant change in vincristine uptake in the presence of the OATP transporter 
inhibitor rifamycin SV in SHH. 
 
Identification of the benzbromarone-sensitive efflux transporter 
Effect of 2 µM of MDR1 inhibitors elacridar, tariquidar and valspodar was assessed on the 
uptake of vincristine (Figure 5) in cryopreserved suspended rat and human hepatocytes to rule out 
the contribution of P-gp in vincristine efflux in suspended hepatocytes. No significant effect was 
observed of the MDR1 inhibitors on the uptake of vincristine whereas benzbromarone (100 µM) 
increased the uptake of vincristine in both species. To evaluate which MRP transporter could be 
involved in vincristine disposition in suspended hepatocytes, uptake of vincristine was assessed 
in MRP1, MRP2 and MRP3 inside-out membrane vesicles (Figure 6). No significant difference 
was observed in the uptake of vincristine in the presence of either ATP or AMP. To validate the 
vesicle assay for assessing vincristine efflux, we showed that in MDR1 vesicles vincristine 
uptake was significantly different in the presence of ATP (Figure 6) (14). Still, benzbromarone 
inhibited the ATP-dependent uptake of E17BDG and CDCF in MRP1, MRP2 and MRP3 
vesicles. It is noteworthy that the absolute difference between CDCF uptake in control and MRP3 
vesicles was low [22 pmol/(min x mg protein)] as compared to CDCF uptake in MRP2 vesicles. 
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Discussion 
Notwithstanding the fact that vincristine is one of the oldest anticancer drugs currently being used 
in clinical practice, some questions regarding vincristine pharmacokinetics remain unanswered 
(5). With respect to hepatic uptake, several studies during the early 90’s investigated the uptake 
processes of vinca-alkaloids vincristine and vinblastine in human and rat hepatocytes. Based on 
these studies, the authors concluded that an energy-independent non-saturable passive diffusion 
process and an energy-dependent saturable active transport system may be involved in the uptake 
of vinca-alkaloids (34). More recently, several publications reported the interference of 
vincristine with OATP1B1 and OATP1B3-mediated uptake processes (30, 31). Additionally, in a 
thesis by T. Loo in 2011, SNPs in genes coding for SLCO1B1 and SLCO1B3 were positively 
correlated with the manifestation of vincristine-induced neurotoxicity (35). The present work was 
therefore aiming to elucidate the potential role of several isoforms of the OATP transporter 
family in the hepatocellular distribution of vincristine. 
 
Experiments with suspended rat hepatocytes clearly showed that vincristine uptake was 
temperature-dependent, with a 7.6-fold lower uptake at 4°C (Figure 1). These data are in line 
with temperature-dependent uptake of vinblastine (2.6-fold lower uptake at 4°C) as shown by 
Zhou and coworkers (27). However, temperature-dependency not necessarily indicates that a 
transporter-mediated process is involved, since membrane fluidity may be reduced at 4°C (36, 
37). To identify whether vincristine uptake was in fact mediated by one or more transporters, 
uptake experiments were performed in the presence of several known OATP inhibitors (Figure 
1). Paclitaxel and docetaxel exhibited the most pronounced effect on vincristine uptake, 
confirming the strong interaction of taxanes with OATP transporters (30, 31). Inhibition of 
vincristine uptake in SRH by methotrexate is in line with research performed by Smeland et al., 
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who suggested a competitive interaction between vincristine and methotrexate in SRH (29). 
However, digoxin and quinidine, both OATP1A4/Slc21a5 inhibitors, were unable to significantly 
alter the vincristine uptake process (38). This indicates that vincristine is probably not a good 
substrate for OATP1A4. All other OATP inhibitors (atazanavir, bromosulfophthalein, 
cyclosporine A, glibenclamide, losartan, rifampicin and rifamycin SV) inhibited vincristine 
uptake to a similar extent (40% decrease). Even the well-known MRP inhibitor MK571 was able 
to reduce vincristine entry into SRH. This was not unexpected, since several research groups 
have reported that MK571 is a potent inhibitor of OATP transporters (31). Uptake experiments of 
vincristine in OATP1B1-, 1B3- and 2B1-transfected CHO cell lines resulted in a higher 
vincristine uptake as compared to wild-type CHO cells (Figure 3A). Additionally, uptake of 
vincristine in transfected CHO cells could be inhibited with a series of OATP transporter 
inhibitors (Figures 3B-D). OATP-mediated uptake of vincristine proved to be non-saturable with 
concentrations up to 300 µM (data not shown). Uptake data of vincristine in OATP1B1- and 
OATP1B3-transfected CHO cells were converted for comparison with SHH data by using RAF 
factors which were determined previously by our group (33). Passive uptake data estimated from 
vincristine uptake in wild-type CHO cells [4.1 ± 0.5 µl/(min x million cells)] corresponded well 
to passive uptake clearance observed in SHH at 4°C [3.8 ± 1.3 µl/(min x million cells)] (Table 3). 
However, uptake measurements obtained at 4°C likely underestimate true passive uptake due to 
increased membrane rigidity at low temperature (36, 37). RAF-corrected total uptake clearance 
[1.9 ± 0.3 µl/(min x million cells)] valued 15% of the observed total uptake clearance in SHH 
[13.9 ± 3.7 µl/(min x million cells)]. This appears consistent with the fact that uptake of 
vincristine in SHH could not be inhibited below 90%, using an established OATP transporter 
inhibitor such as rifamycin SV (Figure 4B). It is still plausible that rifamycin SV simultaneously 
inhibited uptake as well as efflux transport (39). As a consequence, inhibition of vincristine 
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uptake would be counteracted by the inhibition of vincristine efflux transport, resulting in an 
insignificant net decrease of 10%. Also, involvement of another unidentified uptake transporter 
could explain the large observed difference between uptake at 37°C and 4°C which was not 
explained by the inhibition of OATP. In view of the relatively large size of vincristine, the 
involvement of OAT2 in hepatic uptake of vincristine can be considered less likely, although we 
cannot exclude this based on the presently available data. Still, rifamycin SV statistically 
significantly decreased vincristine uptake in one batch of SHH by 52.5%. It is also possible that 
this individual (Asian; male; 55 years old) carries a SNP in one of the OATP-coding genes, 
corresponding to a phenotype with increased vincristine uptake. On the other hand, the 
benzbromarone-sensitive efflux transporter may have been less active in this individual, thus 
improving conditions to observe OATP inhibition in the presence of rifamycin SV. 
 
Apart from the observed uptake inhibition, increasing concentrations of MK571 and 
benzbromarone significantly increased the uptake of vincristine in SRH (Figures 2A-B). This 
contrasts to a previous study of Zhou and coworkers, where it was suggested that vincristine 
efflux in suspended hepatocytes was limited (27). Similar results were obtained in SHH in the 
presence of 100 µM of benzbromarone (Figure 4C). Both MK571 and benzbromarone are 
established MRP transporter inhibitors, implying the role of an MRP transporter in the hepatic 
disposition of vincristine (40). Cis-stimulation of the OATP-mediated uptake by benzbromarone 
was ruled out, since it did not increase the uptake of vincristine in the OATP-transfected-CHO 
cells (41). Since vincristine is a well-known MDR1 substrate, we needed to show that 
benzbromarone and MK571 did not inhibit MDR1 in suspended hepatocytes. This was indeed 
ruled out since selective MDR1 inhibitors elacridar, tariquidar and valspodar did not increase the 
accumulation of vincristine in suspended rat and human hepatocytes (Figure 5). This is in line 
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with the internalization of MDR1 in suspended hepatocytes as reported by Bow and coworkers 
(42). Involvement of BCRP was also excluded since it was reported that BCRP did not confer 
resistance to vincristine and internalization of MDR1 would also imply the internalization of 
other canalicular membranes. Among the MRP transporters, it was reported in literature that 
MRP4, MRP5 and MRP6 expression in transfected cell lines did not induce resistance to 
vincristine toxicity (43-45). On the other hand, it is well known that vincristine is a substrate of 
MRP1. However, hepatic MRP1 expression levels in adult hepatocytes are generally considered 
low or non-detectable (46). This reduces the likelihood for MRP1 to have a considerable impact 
on hepatic drug disposition. Presence of MRP2 had also shown to confer resistance to vincristine 
toxicity (16, 47-49). However, since we were unable to increase vincristine accumulation in the 
presence of MDR1-selective inhibitors, we hypothesized that MRP2 would likewise not be 
present or active on the membrane of suspended hepatocytes (42). Several reports claim that 
expression of MRP3 could be linked to vincristine resistance; however literature reports on 
MRP3-mediated vincristine transport are unclear (50-53). Taken together, it seems that MRP3 is 
the only known transporter present in suspended hepatocytes likely to mediate vincristine efflux. 
To verify which transporter mediated vincristine efflux, vincristine uptake was assessed in 
membrane vesicles containing MRP1, MRP2, MRP3. However, we were not able to detect the 
transport of vincristine by MRP1, MRP2 or MRP3 (Figure 6). To ensure that the vesicle assay is 
a suitable system to measure vincristine transport, we showed that we were able to measure the 
ATP-dependent transport of vincristine by MDR1. Still, the hydrophobic nature of vincristine 
could hinder the accurate measurement of vincristine transport in MRP1, MRP2 and MRP3 
containing membrane vesicles. It is known that it is challenging to assess efflux transport of 
hydrophobic compounds in inside-out membrane vesicles (54). Due to this drawback of the in 
vitro system, we do not conclude that vincristine is not transported by MRP1, MRP2 or MRP3. It 
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may also be possible that the expression levels of MRP3 were too low in the currently used 
membrane vesicles to measure the transport of vincristine. Indeed, CDCF transport in control and 
MRP3 containing vesicles did not differ greatly but the uptake could still be inhibited by 
benzbromarone (Figure 7). In a thesis by Loo in 2011, a wide range of ABC transporters were 
significantly correlated with vincristine neurotoxicity (ABCA4, ABCB5, ABCG1, ABCC4, 
ABCA1, ABCC1/6, ABCB1, ABCC8, ABCC3, ABCC10, ABCC2) (35). Instead of toxicity 
studies, actual transport of vincristine should be evaluated in transfected cell lines or membrane 
vesicles containing other transporters to identify which transporters are involved. Alternatively, 
inhibition studies with selective MRP inhibitors could help to identify this elusive efflux 
transporter. A transporter of the MRP family likely corresponds to the unidentified efflux 
transporter since benzbromarone and MK571 are notorious MRP inhibitors. However, MRP 
transporters require ATP for their activity and Watanabe and coworkers reported no change in the 
uptake of vincristine in SRH upon depletion of ATP (55). Thus, an ATP-independent 
benzbromarone-sensitive efflux transporter, not related to the MRP family, may also be 
responsible for vincristine efflux in SRH (e.g. MATE1, OSTα/β). Further research is therefore 
warranted to elucidate the identity of this important transporter for hepatocellular vincristine 
disposition.  
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Conclusion 
In conclusion, OATP transporters are involved in the disposition of vincristine in suspended rat 
and human hepatocytes. However, efflux transport, potentially by the sinusoidal efflux 
transporter MRP3, overshadows the effect of OATP-mediated transport. The exact role of uptake 
and efflux transporters should be further investigated to enable mechanistic modeling of 
vincristine disposition. The present and future findings on vincristine disposition pathways could 
help researchers to explain the large inter-individual variability in vincristine exposure and 
improve patient-specific dose selection. 
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Tables 
Table 1. Demographic and medical information on human hepatocyte donors used in the current 
study and used in the article by De Bruyn and coworkers to calculate the RAF factors for 
OATP1B1 and OATP1B3 (33). 
Batch Sex Age Race Cause of death Medical history 
YUA M 40 Caucasian Stroke 
Alcohol use, tobacco use, medication 
for hypertension 
QWG F 58 Caucasian CVA NA. 
HRU M 55 Asian Intracranial bleed NA. 
JCM F 77 Caucasian Intracranial bleed Alcohol (2-3 drinks per month) 
MNO M 80 Caucasian CVA Tobacco use 
KCM F 40 Black Intracranial bleed 
Alcohol use, tobacco, potentially 
marijuana, medication for 
hypertension, diabetes and cholesterol 
GUY M 39 Caucasian Intracranial bleed Cocaine use, alcohol use 
FDX* 10M/10F 52 17C, 2B, 1H *** *** 
ZKO** 25M/25F 54 42C, 5B, 3H *** *** 
RAF-
Pool (33) 
2M/3F 43 Caucasian # # 
Age in years, average age depicted for donor pools, * 20-donor pool, **50-donor pool,*** information 
can be requested from Bioreclamation IVT, RAF-Pool refers to the batch of pooled human hepatocytes 
used by De Bruyn and coworkers to calculate the RAF factors for OATP1B1 and OATP1B3 (33), # 
information can be requested from CellzDirectTM for batches Hu4050, Hu8067, Hu4140, Hu4128 and 
Hu8008. 
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Table 2. Relative activity factors (RAF) applied to calculate vincristine uptake clearance in SHH 
from vincristine uptake in OATP1B1- and OATP1B3-transfected CHO-cells. 
RAF-factor Estrone-3-sulfate CGamF 
RAFOATP1B1 0.70 N.A. 
RAFOATP1B3 N.A. 0.11 
RAF factors for these cell-lines were determined previously within our research group (33) by comparison 
with a pool of suspended human hepatocytes. 
 
Table 3. Vincristine uptake clearance [µl/(min x million cells)] in CHO cells, corrected with RAF 
factors for OATP1B1 and OATP1B3 activities (Table 2), compared to average vincristine uptake 
clearance values in SHH. 
Cell line ClCHO ClSHH,estimated Condition ClSHH,observed 
wild-type 2.1 ± 0.2 4.1 ± 0.5 4°C 3.8 ± 1.3 
OATP1B1 1.9 ± 0.4 1.3 ± 0.3 / / 
OATP1B3 5.7 ± 0.5 0.6 ± 0.1 / / 
TotalOATP / 1.9 ± 0.3 37°C-4°C 10.1 ± 1.5 
Total / 6.0 ± 0.6 37°C 13.9 ± 3.7 
ClCHO: vincristine uptake clearance in CHO cells, ClSHH,estimated: vincristine uptake clearance from CHO-
cells which has been recalculated with RAF factors, ClSHH,observed: vincristine uptake clearance observed in 
SHH experiments. Values represent means ± SD.  
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Legend to Figures 
 
Figure 1. Effect of temperature and OATP inhibitors (10 µM) on the uptake of vincristine (0.5 
µM) in SRH. Every inhibitor except for digoxin and quinidine significantly inhibited vincristine 
uptake. Bars represent means ± SD of triplicate incubations in two preparations of SRH. 
Conditions were compared to uptake at 37°C in SRH. (* p < 0.05; *** p < 0.001) 
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Figure 2. Effect of increasing concentrations of MRP inhibitors MK571 (A) and benzbromarone 
(B) on the uptake of vincristine (0.5 µM) in SRH as compared to the control condition (white 
bar). Bars represent means ± SD of triplicate incubations in one batch of SRH. (ns. not 
significant; * p < 0.05; *** p < 0.001) 
 
37 
 
 
Figure 3. (A) Comparison of vincristine (10 µM) uptake in wild-type and OATP1B1-, 1B3- and 
2B1-transfected CHO-cells. Uptake of vincristine was significantly higher in all transfected 
CHO-cells as compared to the uptake in wild-type cells. (B-D) Effect of different OATP inhibitors 
(10 µM) on the net uptake (wild-type subtracted uptake) of vincristine in OATP1B1-, OATP1B3- 
and OATP2B1-transfected CHO-cells. Bars represent means ± SD of triplicate incubations in 
two preparations of CHO-cells. (* p < 0.05; ** p < 0.01; *** p < 0.001) 
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Figure 4. Effect of temperature (A), rifamycin SV (B) and benzbromarone (C) on the uptake of 
vincristine (0.5 µM) in SHH. Points represent the means of triplicate incubations in multiple 
batches (n = 8) of SHH. (ns. not significant; *** p < 0.001) Paired Student’s t-tests were used to 
compare groups in all conditions (data were normally distributed). Uptake of vincristine only 
differed statistically significantly in one batch of SHH (HRU; p = 0.0057; 6B). Each symbol 
represents a different batch of SHH. 
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Figure 5. Effect of temperature, benzbromarone (100 µM) and selective P-gp inhibitors 
elacridar, tariquidar and valspodar (2 µM) on the uptake of vincristine (0.5 µM) in (A) 
cryopreserved rat hepatocytes and (B) cryopreserved human hepatocytes. Bars represent means 
± SD of triplicate incubations in single batches of hepatocytes. ( *** p < 0.001) 
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Figure 6. Uptake of vincristine (200 nM) in inside-out membrane vesicles containing MRP1, 
MRP2, MRP3 or MDR1, normalized for uptake in control vesicles in presence of either ATP or 
AMP. Bars represent means ± SD of triplicate incubations in single batches of inside-out 
membrane vesicles. (* p < 0.05) 
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Figure 7. (A) Uptake of E17BDG (10 µM)  in control and MRP1 containing inside-out 
membrane vesicles. (B) Uptake of CDCF (10 µM) in control, MRP2 and MRP3 containing 
inside-out membrane vesicles in presence of either ATP or AMP with or without benzbromarone 
(100 µM). Bars represent means ± SD of triplicate incubations in single batches of inside-out 
membrane vesicles. (* p < 0.05). 
